Table 1.
Patient characteristics in the UI Health cohort and dbGaP samples.
| UI cohort n (%) | dbGaP samples n (% of reported) | |
|---|---|---|
| Sample size | 33 | 541 |
| Age at baseline (years) | ||
| Percent reported | 100% | 15.0% |
| Median | 63.4 | 72 |
| Range | 51.9–77.7 | 39–92 |
| Self-reported race | ||
| Percent reported | 100% | 14.8% |
| Black/AA | 23 (69.7) | 1 (1.25) |
| White | 7 (21.2) | 77 (96.3) |
| Unknown | 2 (6.0) | 0 (0) |
| American Indian | 1 (3.0) | 1 (1.25) |
| Asian | 0 (0) | 1 (1.25) |
| Self-reported ethnicity | ||
| Percent reported | 100% | 0% |
| Non-Hispanic | 27 (81.8) | |
| Hispanic | 6 (18.2) | |
| Baseline PSA | ||
| Percent reported | 100% | 4.62% |
| Median | 226 | 5.3 |
| Range | 7.97–5800 | 2.8–13.7 |
| Stage at diagnosis | ||
| Percent reported | 100% | 0% |
| Localized (N0) | 4 (12.1) | |
| Regional (N1) | 6 (18.2) | |
| Metastatic (de novo) | 23 (69.7) | |
| Tissue sequenced | ||
| Percent reported | 100% | 100% |
| Localized tumor | 33 (100) | 101 (19.3) |
| Metastases | 310 (59.2) | |
| CRPC | 115 (21.9) | |
| NEPC | 15 (2.86) | |
| Gleason sum | ||
| Percent reported | 100% | 4.62% |
| ≤7 | 5 (15.2) | 19 (76) |
| ≥8 | 24 (72.3) | 6 (24) |
| Unknown | 4 (12.1) | 0 (0) |
Abbreviation: NEPC, neuroendocrine prostate cancer.